Endogenous retroelements in cellular senescence and related pathogenic processes: Promising drug targets in age-related diseases

Research output: Contribution to journalArticlepeer-review

Abstract

Endogenous retroelements (ERs) represent nearly half of the human genome. Considered up to recent years as “functionless” DNA sequences, they are now known to be involved in important cellular functions such as stress response and generation of non coding regulatory RNAs. Moreover, an increasing amount of data supports the idea of ERs as key players in cellular senescence and in different senescence-related pathogenic cellular processes, including those leading to inflammation, cancer and major age-related multifactorial diseases. The involvement of ERs in these biological mechanisms can suggest new therapeutic strategies in neoplasms, inflammatory/autoimmune diseases and in different age-related pathologies, such as macular degeneration, diabetes, cardiovascular diseases and major age-related neurodegenerative disorders. The therapeutic approaches which can be suggested range from a set of well-known, common drugs that have been shown to modulate ERs activity, to immune therapy against ER-derived tumor antigens, to more challenging strategies such as those based on anti-ERs RNA interference.

Original languageEnglish
Pages (from-to)416-427
Number of pages12
JournalCurrent Drug Targets
Volume17
Issue number4
Publication statusPublished - Mar 1 2016

Keywords

  • Age-related diseases
  • Alu
  • Cancer
  • Cellular senescence
  • Drugs
  • Inflammation
  • LINE-1
  • Retrotransposons

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Endogenous retroelements in cellular senescence and related pathogenic processes: Promising drug targets in age-related diseases'. Together they form a unique fingerprint.

Cite this